Parminder studied medicine at The University of Birmingham (2001-2006). She began training in nephrology in Oxford in 2010.
Parminder has taken time “out-of-programme for research” from her nephrology training and joined the Renal Studies Group at CTSU in 2013 as a Clinical Research Fellow. She works on the UK Heart and Renal Protection (HARP)-III trial, which is testing new treatments in patients with chronic kidney disease and has also worked on the 3C trial.
Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data.
UK HARP-III Collaborative Group None., (2017), Nephrol Dial Transplant, 32, 2043 - 2051
Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome.
Gross O. et al, (2017), Nephrol Dial Transplant, 32, 916 - 924